Estonia

Estonia has a restrictive controlled-substances framework for psychedelics. Classic psychedelics such as psilocybin, LSD, MDMA, DMT and related substances are listed under the national narcotic/psychotropic substances regime, so use outside medical or scientific purposes is prohibited.

Ask Blossom about this country

Data updated May 18, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inEstonia.

1
The ecosystem is research-led rather than access-led: the most visible Estonia-linked psychedelic work is a single recruiting depression trial rather than a broad treatment market.
2
University hospital psychiatry in Tartu provides the clearest institutional anchor for mental-health research and complex care, but its public pages do not indicate routine psychedelic treatment services.
3
Esketamine is the clearest legally integrated rapid-acting antidepressant signal in Estonia, but the available official material points to regulated clinical use, not open routine access.
4
The legal environment appears stable and conservative, with recent 2026 schedule updates focused on other psychoactive substances rather than any liberalisation of psychedelics.
5
Given the tiny number of linked trials, stakeholders and events in Blossom, Estonia looks like a small but credible node for monitored psychiatric research rather than a destination with notable patient access.

Research and Access Snapshot

Blossom currently tracks 5 psychedelic clinical trials connected to Estonia, including 1 active study.

Active trials: 1
Total trials: 5
Stakeholders: 3
Events: 1

Top Compounds

Esketamine(3)

Active Trial Preview

View all trials →

Effect of Psychedelic VR-augmented Therapy on Patients With Clinical DepressionRecruiting - NA

Medical Access

Estonia maintains a restrictive controlled-substances regime: classic psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine, ayahuasca preparations) are scheduled and have no routine medical reimbursement outside authorised clinical research. One exception in clinical psychiatric care is esketamine (Spravato) which holds an EU marketing authorisation and is registered for use - however, its use in Estonia is delivered through medical prescription/clinic pathways and is not generally available as a routinely reimbursed, publicly funded...

View trials→View stakeholders→View events→Open access guide→

Regulatory Status

Medical access is narrow. The State Agency of Medicines states that narcotic and psychotropic substances are regulated for medical and scientific handling only, and that ketamine and esketamine injectables may not be prescribed or dispensed from pharmacies in standard form; Estonia's medicines statistics also show esketamine use, consistent with authorised clinical pathways rather than routine public access. Classic psychedelics remain controlled, and any non-standard use would generally require authorised research or special import/handling permissions. The exact reimbursement position for psychiatric ketamine/esketamine can vary by product and setting, so that element should be treated cautiously.